Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : EU drugs regulator to decide on Pfizer vaccine booster in early October

09/23/2021 | 12:12pm EDT

* EMA cites increase in breakthrough infections

* Review of boosters for the immunocompromised also ongoing

Sept 23 (Reuters) - The European Medicines Agency (EMA) aims to decide in early October whether to endorse a third dose of the Pfizer-BioNTech COVID-19 vaccine to be given half a year after the initial two-shot course, saying breakthrough infections added some urgency to its review.

"The outcome of this evaluation is expected in early October, unless supplementary information is needed," EMA's head of vaccines strategy, Marco Cavaleri, told a press briefing on Thursday.

Cavaleri's statement confirmed a Reuters report earlier in the day on EMA's expected review time on the matter.

The U.S. Food and Drug Administration on Wednesday authorized a third dose of Pfizer for those aged 65 and older, all people at high risk of severe disease, and others who are regularly exposed to the coronavirus.

The EU regulator said on Sept. 6 it had begun its evaluation of data submitted by Pfizer and BioNTech for a booster dose to be given six months after the second dose in people 16 years of age and older.

Moderna is also expected to submit data to the EMA this month on its booster dose, an EU document said.

EMA added that, in early October at the latest, it would conclude its review of the use of both the Pfizer-BioNTech and the Moderna shots in people with a weak immune system already one month after their initial two-shot regimen.

"The evidence is becoming clearer on the need to consider this option for people who may respond poorly to COVID-19 vaccination, such as immunocompromised individuals," said Cavaleri.

In an opinion issued in early September and republished by the EMA, the European Centre for Disease Prevention and Control (ECDC) said there was no urgent need to administer booster doses to fully vaccinated people in the general population.

But many EU states have already decided to administer a booster dose despite facing higher legal risks without a formal decision to do so by the EMA.

EMA on Thursday conceded there may be merits in doing so.

"With an increase in breakthrough cases that we've seen over time, we do understand that member states in Europe and countries elsewhere want to consider now the option of a booster, particularly in vulnerable groups and that is why we have been expediting our review," said Cavaleri.

He added he expects Pfizer and BioNTech to submit data on vaccine use in children aged five to 11 years in early October, and similar data from Moderna in early November, with a review likely taking around four weeks if no further data is required.

On CureVac's request for vaccine approval, the EMA official said that by the end the year the watchdog should be "in a better position to really understand what could be the next step for this vaccine". CureVac in June and July published disappointing trial data.

The EU has signed three deals with Pfizer and BioNTech for a total of 2.4 billion doses.

The latest contract covers the supply of at least 900 million shots, a large part of which is likely to be needed only if boosters are considered necessary, or if new virus variants emerge against which existing vaccination is not effective.

Over 70% of the EU's adult population has already been fully vaccinated, and the bloc has secured an ample supply of vaccines from several manufacturers.

The ECDC has said crucial data on the need and safety of boosters are still missing, in part because it is not yet fully clear how long vaccines protect against the virus. (Reporting by Emilio Parodi, Francesco Guarascio, Pushkala Aripaka and Ludwig Burger; editing by Grant McCool)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
MODERNA, INC. -3.84% 326.54 Delayed Quote.212.57%
PFIZER, INC. 0.70% 43.16 Delayed Quote.16.44%
All news about MODERNA, INC.
02:53pMODERNA : U.S. CDC Says Delivered 503,521,625 Doses Of Covid-19 Vaccine As Of Oct 23
RE
10/22MODERNA : Canada considers what to do with millions of unused COVID-19 vaccine doses
AQ
10/22MODERNA : U.S. administers nearly 412 mln doses of COVID-19 vaccines - CDC
RE
10/22MODERNA : COVID SCIENCE-COVID-19 vaccines not linked to pregnancy loss; mixing vaccines ma..
RE
10/22CVS HEALTH : Pharmacies Start Offering Moderna COVID-19 Booster Shots
MT
10/22EXPLAINER : Is it time to get a COVID-19 booster? Which one?
AQ
10/22MODERNA : Deutsche Bank Starts Moderna at Sell with $250 Price Target
MT
10/22Walgreens Starts Offering Moderna, Johnson & Johnson COVID-19 Booster Shots
MT
10/22CDC approves Moderna, J&J COVID-19 boosters, mixing and matching doses
AQ
10/22BB BIOTECH AG : BB Biotech: i ricavi -2-
DJ
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2021 20 374 M - -
Net income 2021 12 558 M - -
Net cash 2021 13 559 M - -
P/E ratio 2021 10,9x
Yield 2021 -
Capitalization 132 B 132 B -
EV / Sales 2021 5,80x
EV / Sales 2022 5,10x
Nbr of Employees 1 300
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Last Close Price 326,54 $
Average target price 295,79 $
Spread / Average Target -9,42%
EPS Revisions
Managers and Directors
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.38%49 092
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-38.86%25 455
ALNYLAM PHARMACEUTICALS, INC.52.81%23 604